Medtronic (MDT +0.3%) says it's successfully completed the first phase of feasibility studies on its next-generation renal denervation system, which features a simultaneously firing multi-electrode catheter and advanced radio-frequency generator. A total of nine patients were treated with a 100% acute success rate in accessing the vessels and delivering therapy. The system is only in its investigational phase however, and isn't yet commercially available anywhere in the world.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Thu, 5:10PM)
at Zacks.com (Feb 24, 2015)
UPDATE: Medtronic plc: FDA Approves the VenaSeal Closure System for Treatment of Clinically Symptomatic Venous Refluxat Benzinga.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
at Investor's Business Daily (Feb 19, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs